Caption Management’s Atara Biotherapeutics ATRA Stock Holding History

Caption Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,080	Closed	-$405K	–	1483
2022 Q2	$405K	Buy	+2,080	New	+$340K	0.01%	1118

Other funds holding ATRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Caption Management's ATRA Position: Q3 2022 in Review

Caption Management sold out of Atara Biotherapeutics (ATRA) in Q3 2022, closing a stake of 2,080 shares — an estimated $405K sold.

Caption Management first reported a position in ATRA in Q2 2022 and held it in 1 quarter. The position peaked at $405K in Q2 2022. 154 funds tracked by Wall St. Rank hold ATRA as of Q3 2022.

Caption Management reported no remaining Atara Biotherapeutics position as of Q3 2022 after selling out during the quarter.
Caption Management sold 2,080 Atara Biotherapeutics shares in Q3 2022, an estimated $405K.
Caption Management first reported a position in Atara Biotherapeutics in Q2 2022 and held it in 1 quarter.
Caption Management's Atara Biotherapeutics position peaked at $405K in Q2 2022.
154 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2022.

Based on Caption Management's 13F filing for Q3 2022, filed 14 Nov 2022.